CEO Pascal Soriot emphasized that AstraZeneca's total revenue grew by ... Revenue growth in Q1 2025 was 10%, compared to 21% in Q4 2024. The gross margin improved slightly due to favorable FX.

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ ... with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider ...

It is one of the best UK stocks to buy. Overall, 55 hedge funds were bullish on AstraZeneca PLC (NASDAQ:AZN) in Q4 2024, and it was part of 14 billionaire portfolios that had combined stakes worth ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of 2025 from $18.8bn in Q4 2024 to $37.7bn ... GSK’s $1.15bn buy of IDRx, ...

AstraZeneca (AZN): The 0.64% AZN position was ... Data constructed from Fisher Asset Management’s 13F filings for Q4 2024 and Q1 2025. Editor's Note: This article discusses one or more ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

New Delhi: India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade ...

The largest company, AstraZeneca, fought back from a 4% fall in early trading ... are down 3.75% on the back of its 2024 results, which had a first-quarter update tagged alongside them. The owner of ...